Jefferies analyst David Windley reiterated a Buy rating on Charles River Labs (CRL) yesterday and set a price target of $158. The company’s shares closed yesterday at $136.23, close to its 52-week high of $138.89.
According to TipRanks.com, Windley is a top 25 analyst with an average return of 22.9% and a 81.8% success rate. Windley covers the Services sector, focusing on stocks such as Molina Healthcare, Centene Corp, and Anthem Inc.
Currently, the analyst consensus on Charles River Labs is a Moderate Buy with an average price target of $139.83, representing a 2.6% upside. In a report released yesterday, Robert W. Baird also maintained a Buy rating on the stock with a $148 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $138.89 and a one-year low of $96.70. Currently, Charles River Labs has an average volume of 364.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions.
